Åukasz KuÅ^obicki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/536631/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Research, 2006, 16, 29-36.	1.2	60
2	Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours. Melanoma Research, 2007, 17, 139-145.	1.2	46
3	JARID1B expression in human melanoma and benign melanocytic skin lesions. Melanoma Research, 2013, 23, 8-12.	1.2	24
4	The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions. Melanoma Research, 2012, 22, 70-76.	1.2	20
5	Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions. Melanoma Research, 2006, 16, 435-444.	1.2	16
6	Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma. Melanoma Research, 2016, 26, 448-456.	1.2	16
7	Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies. Melanoma Research, 2009, 19, 294-300.	1.2	14
8	Different expression of cyclooxygenase-2 (COX-2) in selected nonmelanocytic human cutaneous lesions. Folia Histochemica Et Cytobiologica, 2011, 49, 381-388.	1.5	14
9	Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Research, 2006, 16, 235-243.	1.2	8
10	Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients. BMC Cancer, 2014, 14, 732.	2.6	7
11	Prognostic significance of RBP2-H1 variant of JARID1B in melanoma. BMC Cancer, 2017, 17, 854.	2.6	6
12	Different detectability of cyclooxygenase-2 (COX-2) protein in standard paraffin sections and tissue microarrays of human melanomas and naevi – Comparative study. Pathology Research and Practice, 2014, 210, 591-595.	2.3	4
13	Immunohistochemical detectability of cyclooxygenaseâ€⊋ expression in cells of human melanocytic skin lesions: A methodological review. Journal of Cutaneous Pathology, 2020, 47, 363-380.	1.3	4
14	Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 357-364.	1.2	3
15	Altered Splicing of JARID1B in Development of Human Cutaneous Melanoma?. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 188-192.	1.2	2
16	Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?. Oncotarget, 2018, 9, 17656-17663.	1.8	2
17	The detectability of intraepidermal melanocytes ―a narrative review of immunohistochemical studies. Journal of Cutaneous Pathology, 0, , .	1.3	2
18	Cyclooxygenase-2 overexpression as indicator of favorable clinicopathological phenotype and better survival of colorectal cancer patients: Fact or artifact?. Basic and Applied Pathology, 2011, 4, 33-33.	0.2	1

#	Article	IF	CITATIONS
19	Expression of Cyclooxygenase-2 in Human Epithelial Skin Lesions. Applied Immunohistochemistry and Molecular Morphology, 2020, Publish Ahead of Print, 163-174.	1.2	1